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Abstract
Purpose Over 80% of the terminally ill patients experience
delirium in their final days. In the treatment of delirium, hal-
operidol is the drug of choice. Very little is known about the
pharmacokinetics of haloperidol in this patient population. We
therefore designed a population pharmacokinetic study to gain
more insight into the pharmacokinetics of haloperidol in ter-
minally ill patients and to find clinically relevant covariates
that may be used in developing an individualised dosing
regimen.
Methods Using non-linear mixed effects modelling
(NONMEM 7.2), a population pharmacokinetic analysis was
conducted with 87 samples from 28 terminally ill patients who
received haloperidol either orally or subcutaneously. The co-
variates analysed were patient and disease characteristics as
well as co-medication.
Results The data were accurately described by a one-
compartment model. The population mean estimates for oral
bioavailability, clearance and volume of distribution for an
average patient were 0.86 (IIV 55%), 29.3 L/h (IIV 43%)
and 1260 L (IIV 70%), respectively. This resulted in an aver-
age terminal half-life of haloperidol of around 30 h.
Conclusion Our study showed that the pharmacokinetics of
haloperidol could be adequately described by a one-
compartment model. The pharmacokinetics in terminally ill
patients was comparable to other patients. We were not able
to explain the wide variability using covariates.
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Introduction
In palliative care, (terminal) delirium is a frequently seen
symptom with over 80% of the advanced cancer patients
experiencing delirium in their final days [1]. Although
randomised clinical trials are scarce, most guidelines and spe-
cialist consider haloperidol, a typical/classic antipsychotic, to
be the first-line treatment of delirium [2–4]. Haloperidol is
metabolised by several different pathways, involving cyto-
chrome P450 (CYP), carbonyl-reductase and uridine
diphosphoglucose glucuronosyltransferases (UGT) enzymes.
Glucuronidation appears to be the major metabolic route
followed by the reversible reduction of haloperidol to reduced
haloperidol and CYP-mediated oxidation by CYP3A and
CYP2D6.
The dose of haloperidol is determined based on the clinical
effect. As haloperidol can cause motor (or extrapyramidal)
and cardiovascular adverse/side effects, it is normally started
at a low dose (0.5–2.0 mg) and increased slowly until the
desired effect is reached. This can be disadvantageous in the
case of refractory symptoms when rapid symptom relief is
required. In addition, haloperidol has a relative long terminal
half-life (t1/2) of approximately 20 h causing steady state to be
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reached after 4 to 5 days. Patients could therefore potentially
benefit if an individualised dose is determined beforehand. In
palliative patients, this is even more important, as rapid symp-
tom relief is essential in the last phase of life.
Several studies on the pharmacokinetics of haloperidol in
healthy volunteers or psychiatric patients showed large inter-
individual variability (IIV) [5–11]. As haloperidol has a mod-
erate hepatic extraction ratio of 0.3–0.7, its metabolism may
be influenced by hepatic blood flow as well as intrinsic en-
zyme activity and protein binding [7, 12, 13]. Therefore, the
IIV in palliative care patients may be even more pronounced
as these patientsmay suffer from decreased blood flow, altered
plasma protein levels and possibly hepatic dysfunction [14].
We performed a population pharmacokinetic study in termi-
nally ill patients to gain more insight into the pharmacokinet-
ics in this population and to find clinically relevant parameters
for dose individualisation.
Methods
The study was performed in accordance with the principles of
the Declaration of Helsinki and its later amendments. Ethical
approval was obtained from the Medical Ethics Committee of
the Erasmus University Medical Centre, Rotterdam, and all
patients provided written informed consent.
Data
Data was collected in the palliative care centre, Laurens
Cadenza Zuid in Rotterdam, The Netherlands, during 2 years.
Patients were eligible if they had a terminal illness, survival
prognosis of more than 2 days and less than 3 months and
administration of haloperidol. Informed consent was asked
shortly after admittance to the palliative care centre, and in-
cluded patient were followed until the time of death, unless
informed consent was withdrawn at any point. Only patients
who can give their consent themselves were asked for consent.
The patients gave consent after contacting their family about
the study. The partner/legal representative cosigned the in-
formed consent form as witness of the consent. The investi-
gator kept close contact with the patients and their family
during the study. In the terminal phase, when the patient can-
not be asked anymore, all aspects of the study were commu-
nicated with the family.
Haloperidol was given to treat deliria and was dosed in
accordance with the current guidelines [4]. Haloperidol was
administered orally (either as tablets or as a liquid formula-
tion) or via subcutaneous bolus injection. The exact times of
administration were recorded in the patient record. Any con-
comitant medication was also registered in the patient’s re-
cord. Demographic characteristics (age, gender, weight, race,
primary diagnosis and time of death) were extracted from the
electronic medical records.
Blood sampling and assay
Blood samples were collected randomly via sparse sampling
in both the pre-terminal and terminal phases on average at one
to two occasions during the day, with a maximum of ten a
week, 0.5 to 1 mL of blood. The moment of sampling is not
strictly defined, but follows the clinical condition of the pa-
tient. For example, before and after the change to another
administration route or in case of inadequate effect of a drug,
blood will be sampled. Blood for clinical chemistry is routine-
ly sampled by venous puncture. For this study, sampling is as
much as possible combined with those venous punctures.
Otherwise, sampling from an indwelling venous catheters is
preferred. With the terminal phase being the last hours or days
before death, a patient becomes bedbound, semi-comatose,
and is not able to take more than sips of fluid [15]. During
the terminal phase, blood is sampled only from an indwelling
venous catheter. This method prevents repeated puncturing
and causes minimal or no discomfort to the patient. The sam-
ples were centrifuged after which the plasma was collected
and stored at −80 °C until analysis. The blood samples
were preferably collected at the same time as sampling for
clinical chemistry (standard of care). In the clinical chem-
istry samples, serum levels of albumin, creatinine, urea,
bilirubin, gamma-glutamyl transpeptidase (GGT), alkaline
phosphatase (ALP), alanine transaminase (ALT), aspartate
transaminase (AST) and C-reactive protein (CRP) were
determined.
Haloperidol concentrations were analysed in the plasma
samples using LC-MS/MS with electrospray ionisation in
the positive ionisation mode on a Shimadzu LC-30
(Nishinokyo-Kuwabaracho, Japan) system coupled to an AB
Sciex (Framingham, MA, USA) API5500Q MS. Seventy-
five-microlitre acetonitrile/methanol 84:16 (v/v%) containing
the internal standard haloperidol-d4 was added to 10 μL of
patient’s plasma to precipitate proteins. Afterwards, samples
were vortexed and stored at −20 °C for 30 min to optimise
protein precipitation, vortexed again and centrifuged. Three-
microlitre sample was injected onto a Thermo Scientific
Hypersil Gold (50 × 2.1 mm, 1.9 μm) column. A stepwise
chromatographic gradient was applied using 0.05% ammoni-
um formate/0.10% formic acid in water asmobile phase A and
acetonitrile as mobile phase B. The flow rate was 0.4 mL/min
and the column was kept at 40 °C. Using multiple reaction
monitoring (MRM) with positive ionisation mode, haloperi-
dol was measured as [M+H]+ using the mass transition 376.1/
165.1. The lower limit of quantification was 0.5 μg/L and the
method was validated over a range of 0.5–125 μg/L. The
accuracies ranged from 93.5 to 107.4%.
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Software
Pharmacokinetic analysis was conducted by the
NONMEM® Version 7.2 (ICON Development Solutions,
Ellicott City, MD), PsN® (version 4.4.8), R (version
3.3.0) and Pirana (version 2.9.2).
Population pharmacokinetic method
Log-transformed plasma haloperidol concentrations were
used and the bioavailability of subcutaneous haloperidol was
assumed to be 100% [16]. One-compartment and two-
compartment models were tested for haloperidol using the
first-order conditional estimation method with interaction
(FOCE + I). To account for the two different administration
routes (oral and subcutaneously), the ADVAN5 subroutine
was used. Interindividual variability (IIV) was assessed on
each parameter using an exponential model. Residual variabil-
ity was included as a combined error model.
As weight has been shown to be a covariate in other halo-
peridol pharmacokinetic models, and as the relationship be-
tween body weight and clearance is well documented, this
effect was tested using algometric scaling [11, 17]. In the
covariate analysis, demographic and disease characteristics
including weight, age, gender, primary diagnosis, renal func-
tion (plasma creatinine and plasma urea), hepatic function
(plasma levels of bilirubin, GGT, ALP, ALT and AST), C-
reactive protein (CRP), albumin and the concomitant use of
CYP2D6 and CYP3A inductors and inhibitors were evaluated
for their influence on clearance (CL), volume of distribution
(Vd) and bioavailability (F). Time to death (TTD) was also
evaluated as a covariate. This parameter cannot be used as a
covariate parameter for a priori prediction of individual phar-
macokinetic changes but it may give insight into quantitative
changes at the end of life that are not predicted by standard
blood chemistry tests. The relationship between covariates
and individual estimates was first investigated graphically
and was further tested with a forward inclusion, backward
elimination approach with P values of 0.05 and 0.001,
respectively.
Continuous covariates were normalised to the population
median values and incorporated as power model functions
(Eq. 1). Categorical covariates were transformed to binary
covariates and incorporated as shown in Eq. 2.
θi ¼ θpop  covicovm
 θcov
ð1Þ
θi ¼ θpop  θcovcovi ; ð2Þ
with θi being the individual model predicted pharmacokinetic
parameter (e.g. clearance) for an individual with covariate
value covi, θpop being the population estimate for that param-
eter, covm representing the median covariate value and θcov the
covariate effect. In the equation, for categorical covariates,
covi is either 1 or 0.
To evaluate the time to death (TTD) as a covariate, time-
dependency of the parameters was modelled as a first-order
process given to following equation (Eq. 3).
θi ¼ θpop−θΔ  exp −θrate  TTDð Þ; ð3Þ
in which θΔ is the change in parameter value from its initial
value and θrate is a first-order rate constant determining the rate
with which the parameter value changes over time.
Model evaluation
Intermediate models were evaluated based on minimum OFV
parameter precision, error estimates, shrinkage values and vi-
sual inspection of the goodness of fit plots. A bootstrap with
500 runs was performed on the final model to evaluate the
validity of the parameters estimates and their corresponding
95% percentile ranges. The final model was evaluated with a
normalised prediction distribution error (NPDE) analysis.
NPDE is a simulation-based diagnostics which can be used
to evaluate models developed on datasets with variable dosing
regimens. The analytical value of this method has been previ-
ously described by Comets et al. [18].
Simulations
To give an illustration of the effect of dose on the plasma
concentrations of haloperidol and the variability, deterministic
simulations were performed. The haloperidol plasma concen-
trations were simulated over a time course of 72 h in which six
subcutaneous doses were administered every 12 h. To show
the interpatient variability, the mean and 90% confidence in-
terval are shown graphically.
Results
A total of 28 terminally ill patients were included in the study.
Their median age was 69.5 years (range 43–93), 54% were
male and all patients had advanced malignancy as primary
diagnosis with the majority (87%) having epithelial tissue
as the primary malignant site. On average at one to two
occasions during the day, with a maximum of ten a
week, 0.5 to 1 mL of blood was collected from the pa-
tient by vena puncture or indwelling venous catheter to
determine drug concentrations.
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An overview of all patient characteristics is given in
Table 1. Oral doses of haloperidol ranged from 0.5 to
2 mg a day and subcutaneous doses ranged from 0.5 to
5 mg a day. A total of 86 blood samples were collected.
26.7% of the concentrations were below the quantification
limit (BQL). On closer inspection, half of these plasma
concentrations were measured in samples taken over
200 h after the last haloperidol dose. Discarding these
resulted in 14.6% BQL data left within 200 h after the
last dose. As this is still more than 10%, the M3 method
of handling BQL data was used to estimate if BQL data
were indeed below the lower limit of quantification of
0.5 mg/L [19, 20]. As this resulted in similar parameter
estimates but stability issues, the M1 method (of
discarding the BQL data) was used for the final model.
Structural model
The data were best described by a one-compartment model
with an additive residual error on logarithmic transformed
concentrations. Since there was limited data available in the
absorption phase, the absorption constants (Ka) could not be
estimated. We therefore derived this value from literature, and
as there was no literature available for the absorption time of
subcutaneous injection of the iv formulation, intramuscular
administration was used as a reference [21]. Changing
this assumption to half of the absorption rate did not
affect the other parameters, which indicates that the
model is stable and not influenced by this assumption.
IIV was included on the parameters CL, F and Vd. As
the IIV on CL and F showed a high degree of correla-
tions (99%), these were fixed to unity with the addition
of an extra theta.
Covariate analysis
Allometric scaling was tested both with an estimated scaling
factor for CL and Vd as well as fixed scaling factors of 0.75
and 1, respectively (Eq. (4)). As the values of 0.75 and 1 lay
within the 95 confidence intervals of the estimated scaling
factors, and because estimating the scaling factors did
not significantly improve the model fit, fixed values of
0.75 and 1 were used. Including allometric scaling sig-
nificantly improved the model fit (ΔOFV 7.47,
P < 0.05) and decreased the IIV on Vd with 13%. If
the weight of an individual was unknown, the median
weight of the population (67 kg) was imputed. This was
the case for 35% of the study population.
θi ¼ θpop  WGTiWGTmedian
 scaling factor
ð4Þ
Besides bodyweight, plasma bilirubin concentration was
significant on the volume of distribution in the forward inclu-
sion. This resulted in statistically significant improvement
of the model fit, with a drop in objective function value
(OFV) of 7.22 points and a decrease in IIV on Vd from 61
to 43.2%, thereby explaining 31% of the IIV on Vd. Both
parameters were not significant in the backward elimina-
tion. After inspecting the individual influence on the de-
crease in OFV using sharkplots, it was shown that for
both covariates, there were two very influencing individ-
uals, with just one individual being responsible for
reaching the statistical significance. Bodyweight and plas-
ma bilirubin were therefore not included in the final mod-
el. An overview of all parameter estimates is given in
Table 2.
Table 1 Patient characteristics over the time course of the study
Characteristics N = 28
Age, years (median, range) 69.5 (43–93)
Male, n (%) 15 (53.6)
Female, n (%) 23 (51.1)
Weight, kg (median, range) 67 (35–108)
Ethnic origin, n (%)
Caucasian 26 (92.9)
Afro-Caribbean 2 (7.1)
Primary diagnosis, n (%)
Neoplasm 28 (100)
Epithelial tissue 25 (89.3)
Connective tissue 1 (3.4)
Haematological 1 (3.4)
Not specified 1 (3.4)
Blood chemistry, serum levels
at admission (median, range)
Albumin, g/L 25 (13–39)
Creatinine, μmol/L 79 (20–673)
Urea, mmol/L 8.3 (1.5–43.4)
Bilirubin, μmol/L 9 (3–256)
Gamma-glutamyl transpeptidase, U/L 57 (7–1055)
Alkaline phosphatase, U/L 117 (20–2117)
Alanine transaminase, U/L 14 (7–116)
Aspartate transaminase, U/L 32 (13–396)
C-reactive protein, U/L 115 (1–346)
Patients using dexamethasonea, n (%) 11 (39.3)
Patients using citaloprama, n (%) 1 (3.4)
Patients using paroxetina, n (%) 5 (17.9)
Duration of stayb, days (median, range) 18.6 (1.5–176.6)
Blood samples collectedc, n (median, range) 3 (1–9)
a During any moment while receiving haloperidol treatment
b From start of first haloperidol dose until time of death
c From the start of the first haloperidol dose
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Model evaluation
Figure 1a, b shows that both the population predictions and
individual predictions were evenly distributed around the line
of unity when plotted against the observations. A bootstrap
analysis of the final model was performed to obtain 95% per-
centile ranges for all parameters. Results of the bootstrap are
shown in Table 2. Evaluation of the predictive performance by
NPDE analysis showed accurate predictive ability, with the
distribution of the NPDEs not significantly deviating from a
normal distribution (with a global adjusted P values of 0.4),
and the majority of the NPDEs laying between the values −2
and 2 (Fig. 1c).
Simulations
The effect of 0.5 mg of subcutaneously administered haloper-
idol every 12 h is shown in Fig. 2. The plasma concentration is
very variable between patients.
Discussion
To our knowledge, this is the first population pharmacokinetic
study of haloperidol in terminally ill adult patients. We were
able to describe the pharmacokinetics of haloperidol with ad-
equate accuracy using a sparse sampling method. The
simulations show the high interpatient variability in the phar-
macokinetics and the effect of the long terminal half-life of
haloperidol. The t1/2 of around 30 h from our study means it
would take a long time to reach steady-state levels and it
would take about 6 days to completely eliminate a single
haloperidol dose from the body.
The covariate analysis did not result in any significant co-
variates. Initially, body weight and plasma bilirubin levels
seemed to be correlated; however, as this was mainly due to
influence of one or two individuals, these were not included as
a covariate in the final model. Body weight was shown to be
correlated in other studies [11, 17]. In our study, body weight
was not registered for all patients and can vary a lot in the
terminal phase, which might explain the lack of this correla-
tion in this group of patients. It does not seem likely that
hepatic dysfunction is correlated with the volume of distribu-
tion. A correlation with clearance seems more logical as hal-
operidol has a moderate hepatic extraction ratio of 0.3–0.7.
The fact that none of the hepatic markers showed a correlation
with clearance may be because of the limited data in our study
or because of the fact that the liver has a high over capacity for
metabolising drugs. Furthermore, the fact that none of the co-
medication showed a correlation with clearance may also be
due to the low number of patients using concomitant medica-
tion at the time of haloperidol use. This is common in the
palliative population as the majority of medication is
discontinued in the palliative phase. In addition, a lack of
effect of co-medication may have been expected as there are
Table 2 Parameter estimates of















F 0.861 18 – 0.76 0.50 0.97
Ka oral route 0.236
a – – – – –
Ka subcutaneous
route
20a – – – – –
CL (L/h) 29.3 11 – 27.6 19.8 32.4
Vd (L) 1260 19 – 1283 794 1982
IIV (%)
F 55 43 37 56 20 218
CL 43 34 29 48 22 131
Vd 70 21 31 65 32 108
Residual
variability
0.258 22 19 0.238 0.144 0.353
F bioavailability, Ka absorption rate, CL clearance, Vd volume of distribution
a The Ka values were fixed to literature values as there were no pharmacokinetic studies on haloperidol solution
via subcutaneous administration; thisKa was calculated from a Tmax of 20min which is the literature value of the
intramusculair route [11]
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several different metabolic pathways involved in the metabo-
lism of haloperidol; therefore, co-medication that affects only
one of these routes will most likely have no effect on the
overall clearance of haloperidol.
There have been previous studies in patients with schizo-
phrenia which showed estimates for clearance which were 1.5
to more than 2 times higher than the 29.3 L/h found in our
study, when corrected for bioavailability of 86% [10, 11].
However, as both studies also reported higher estimates for
the total volume of distribution, these together result in t1/2
values of 25 and 39.5 h which is comparable to the t1/2 of
30 h found in our study. It seems reasonable that terminally
ill patients have a lower clearance and a lower volume of
distribution compared to schizophrenia patients, who on aver-
age are younger and are less physically ill. Another difference
with the study by Pilla Redy et al. is that they found haloper-
idol to be best described by a two-compartment model. This
can possibly be explained by the fact that in our study, we had
more sparse data and were therefore unable to accurately de-
scribe a peripheral compartment and inter-compartmental
clearance. This is supported by the fact that their study had
over 500 samples which still resulted in a broad 95% CI for
the peripheral volume of distribution.
Both studies had weight incorporated in their final model.
Unfortunately, one of the limitations of this study is that for
about one third of the patients, the weight was unknown, and
in fact, if the weight was known, this was a single value
reflecting the weight at admission rather than several measure-
ments over the study period. One of the reasons for the lack of
data on weight is that almost none of the drugs given in the
hospice setting were based on the patient’s weight, and there-
fore, it was unnecessary for clinical practice to collect data on
weight. Another reason is that doctors and nurses were reluc-
tant to weigh patients as it could be disturbing for the patient to
be faced with their weight loss. There are several ways to
handle missing covariate data in population pharmacokinetic
analysis [22]. We tried to incorporate these methods in our
model. However, as we did not find a correlation between
weight and any of the other known covariates, a method to
handle missing data was not feasible. We also tested a model
with different population values or IIV values for known and
unknown weights. This did not result in significant improve-
ments and resulted in large shrinkage values and model insta-
bility due to the already sparse sample numbers, and it was
therefore not feasible to use in the final model.
Probably, the most important limitation, in general, is the
fact that an effective plasma concentration of haloperidol is
still unknown. The study of Pilla Redy et al. showed that the
overall EC50 value was 2.7 mg/L on an overall scale of
schizophrenia, with considerably lower effective concentra-
tions for the positive symptoms (0.5 mg/L) than the negative
symptoms (31 mg/L). When we look at deliria, this may show
more similarities with the positive symptoms of schizophrenia
than the negative. However, the underlying cause in the case
of (terminal) deliria is completely different, making it difficult
to give any target concentrations for haloperidol in terminally
ill population. Reference values of haloperidol are only based
on schizophrenia dosing and more studies on delirium and
PK/PD of haloperidol are needed.
Overall, this study showed that it is possible to describe the
pharmacokinetics of haloperidol with adequate accuracy in
terminally ill patients. We were not able to explain the vari-
ability in the pharmacokinetics using covariates. Before any
recommendations can be made, more research is necessary,
Fig. 1 Goodness of fit plots of the final model. Population predictions
(PRED) versus observations of haloperidol (a), individual predictions
(IPRED) versus observations of haloperidol (b) and the normalised
prediction distribution error (NPDE) distribution plot (c) for of the final
model showing NPDE quantiles
Fig. 2 Simulated plasma profiles of haloperidol 0.5 mg every 12 h. The
mean concentration and 90% confidence interval are presented from a
simulation of 1000 patients
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especially to the pharmacodynamic effects of haloperidol in
this population as well as the possible effect of liver failure.
The current Dutch guidelines recommends a dose of 0.5–2 mg
subcutaneously every half an hour until an adequate effect is
reached. Looking at the simulated plasma profiles in our study
and keeping inmind the lack of any known effective dose, this
seems a very reasonable recommendation, as the absorption
constant of haloperidol is fast. The effect can probably be
adequately assessed after half an hour and titrating up. Too
fast dosing may result in adverse events that would take a long
time to wear off due to the long terminal half-life.
In conclusion, this study describes the pharmacokinetics of
haloperidol with adequate accuracy in terminally ill patients.
More information on pharmacodynamics are needed to opti-
mise dosing regimens of haloperidol in this patient group
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